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Supplementary Appendix: 
Table 1. Baseline characteristics of in IPF Cohort, period 1. 
IPF Cohort 
PA101/Placebo Placebo/PA101 
N 12 12 
Age 64 ± 6 (56-74 years) 69 ± 6 (59-79 years) 
Sex 7 Male / 5 Female 8 Male / 4 Female 
Ethnicity (Caucasian) 10 12 
BMI 30.1 ± 4.5 28.2 ± 2.9 
Time since IPF diagnosis 3.8 ± 2.3 (1 - 8 years) 4.3 ± 4.1 (1 - 13 years) 
Duration of Chronic Cough 4.9 ± 3.0 (2-12 years) 6.3 ± 5.2 (1-16 years) 
VAS Cough Severity 59.8 ± 19.1 63.1 ± 12.5 
LCQ (QOL) 12.9 ± 3.6 12.9 ± 2.7 
Data presented as mean ± SD. IPF = Idiopathic Pulmonary Fibrosis; N= Number; BMI = Body Mass Index; VAS 
= Cough severity Visual Analogue Scale; LCQ = Leicester Cough Questionnaire. 
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Table 2. Baseline characteristics in of CIC Cohort, period 1. 
 CIC Cohort 
 PA101/Placebo Placebo/PA101 
N 13 14 
Age 62 ± 14 (23-73 years) 62 ±  8 (44-73 years) 
Sex 2 Male/11 Female 4 Male/10 Female 
Ethnicity (Caucasian) 13 14 
BMI 25.8 ± 5.0 29.4 ± 6.0 
Duration of Chronic Cough  10.2 ± 6.3 (2-20 years) 9.6 ±12.4 (2-43 years) 
VAS 68.5 ± 17.8 72.3 ± 12.3 
LCQ 11.1 ± 2.7 9.9 ± 2.4 
Data presented as mean ± SD. CIC = Chronic Idiopathic Cough; BMI = Body Mass Index; VAS = Visual Analog 
Scale; LCQ = Leicester Cough Questionnaire.  
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Table 3. Post-hoc Analysis (Non-parametric Testing Using Mixed Effects Model on Ranked Data): Change 
from Baseline in Daytime Cough Frequency at Day 14 in IPF Cohort. 
 Least Squares Means 
Treatment Estimate Standard Error DF t Value p Value Lower CI Upper CI 
PA101 9.5791 1.2978 18 7.38 <.0001 6.8525 12.3057 
Placebo 13.6410 1.3584 18 10.04 <.0001 10.7871 16.4949 
Differences of Least Squares Means (PA101-Placebo) 
Estimate Standard Error DF t Value p Value Lower CI Upper CI 
-4.0619 1.8540 18 -2.19 0.0419 -7.9570 -0.1668 
IPF = Idiopathic Pulmonary Fibrosis; DF = Degrees of Freedom; CI = Confidence Interval. 
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Table 4. Post-hoc Analysis (Parametric Testing with Mixed Effects Model Using Non-transformed Data): 
Change from Baseline in Daytime Cough Frequency at Day 14 in IPF Cohort. 
Least Squares Means 
Treatment Estimate Standard Error DF t Value p Value Lower CI Upper CI 
PA101 -14.5153 5.3138 35.5 -2.73 0.0098 -25.2974 -3.7333 
Placebo 1.3429 5.6158 36.4 0.24 0.8123 -10.0419 12.7277 
Differences of Least Squares Means 
Estimate Standard Error DF t Value p Value Lower CI Upper CI 
-15.8582 7.0077 11.4 -2.26 0.0441 -31.2213 -0.4951 
IPF = Idiopathic Pulmonary Fibrosis; DF = Degrees of Freedom; CI = Confidence Interval. 
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 Table 5. Summary Statistics in Each Period: IPF Cohort 
 Treatment Period 1 (IPF Cohort) 
 Baseline D7 D14 
PA101 (n=12) 67.1 38.7 40.1 
   % Change from baseline   -42% 
Placebo (n=10) 60.3 63.4 58.7 
  % Change from baseline   -3% 
 Treatment Period 2 (IPF Cohort) 
 Baseline D7 D14 
PA101 (n=11) 41.4 37.9 37.7 
   % Change from baseline   -9% 
Placebo (n=11) 42.4 50.1 48.3 
   % Change from baseline   14% 
IPF = Idiopathic Pulmonary Fibrosis. 
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Table 6. Summary Statistics in Each Period: CIC Cohort 
 Treatment Period 1 (CIC Cohort) 
 Baseline D7 D14 
PA101 (n=13) 65 49 35 
   % Change from baseline   -46% 
Placebo (n=12) 53 41 48 
   % Change from baseline   -8% 
 Treatment Period 2 (CIC Cohort) 
 Baseline D7 D14 
PA101 (n=10) 29 32 43 
   % Change from baseline   47% 
Placebo (n=12) 37 27 25 
   % Change from baseline   -34% 
CIC = Chronic Idiopathic Cough. 
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Figure 1. Individual Daytime Cough Frequency Data by Treatment Period in IPF Cohort (PA101 treatment 
period 1) 
 
 
 
First Tx= period 1. 
Second Tx= period 2.  
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Figure 2. Individual Daytime Cough Frequency Data by Treatment Period in CIC IPF Cohort (Placebo 
period 1) 
 
First Tx= period 1. 
Second Tx= period 2. 
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